MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease

Joseph M. Connors, Paul Klimo

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease after six cycles of chemotherapy. Of the 74 evaluable patients, 71 (96%) had a complete response. The actuarial relapse-free survival for the complete responders after 62 months off treatment is 90% (median follow-up from treatment completion was 35 months; range, 4 to 62 months). Actuarial overall survival for all 76 patients including all causes of death is 95% (median follow-up time from diagnosis was 43 months; range, 4 to 70 months). Toxicity was modest. Only one death occurred during treatment, and toxicity-related hospitalization was necessary for only 8% of patients. Failure analysis indicates that a disproportionate number of treatment failures occurred in the subgroup with B symptoms and a mediastinal mass ratio greater than one third the transthoracic diameter. This updated report confirms the efficacy and safety of the MOPP/ABV hybrid program for advanced Hodgkin's disease, which is now being tested in a prospective, randomized, multicenter trial.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalSeminars in Hematology
Volume24
Issue number2 SUPPL. 1
StatePublished - Apr 1 1987
Externally publishedYes

Fingerprint

Hodgkin Disease
Drug Therapy
Vincristine
Procarbazine
Mechlorethamine
Survival
Bleomycin
Mediastinum
Prednisone
Treatment Failure
Doxorubicin
Multicenter Studies
Cause of Death
Hospitalization
Therapeutics
Radiation
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. / Connors, Joseph M.; Klimo, Paul.

In: Seminars in Hematology, Vol. 24, No. 2 SUPPL. 1, 01.04.1987, p. 35-40.

Research output: Contribution to journalArticle

Connors, Joseph M. ; Klimo, Paul. / MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. In: Seminars in Hematology. 1987 ; Vol. 24, No. 2 SUPPL. 1. pp. 35-40.
@article{cbfa3a058dba477583220aaa121498bc,
title = "MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease",
abstract = "Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease after six cycles of chemotherapy. Of the 74 evaluable patients, 71 (96{\%}) had a complete response. The actuarial relapse-free survival for the complete responders after 62 months off treatment is 90{\%} (median follow-up from treatment completion was 35 months; range, 4 to 62 months). Actuarial overall survival for all 76 patients including all causes of death is 95{\%} (median follow-up time from diagnosis was 43 months; range, 4 to 70 months). Toxicity was modest. Only one death occurred during treatment, and toxicity-related hospitalization was necessary for only 8{\%} of patients. Failure analysis indicates that a disproportionate number of treatment failures occurred in the subgroup with B symptoms and a mediastinal mass ratio greater than one third the transthoracic diameter. This updated report confirms the efficacy and safety of the MOPP/ABV hybrid program for advanced Hodgkin's disease, which is now being tested in a prospective, randomized, multicenter trial.",
author = "Connors, {Joseph M.} and Paul Klimo",
year = "1987",
month = "4",
day = "1",
language = "English (US)",
volume = "24",
pages = "35--40",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease

AU - Connors, Joseph M.

AU - Klimo, Paul

PY - 1987/4/1

Y1 - 1987/4/1

N2 - Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease after six cycles of chemotherapy. Of the 74 evaluable patients, 71 (96%) had a complete response. The actuarial relapse-free survival for the complete responders after 62 months off treatment is 90% (median follow-up from treatment completion was 35 months; range, 4 to 62 months). Actuarial overall survival for all 76 patients including all causes of death is 95% (median follow-up time from diagnosis was 43 months; range, 4 to 70 months). Toxicity was modest. Only one death occurred during treatment, and toxicity-related hospitalization was necessary for only 8% of patients. Failure analysis indicates that a disproportionate number of treatment failures occurred in the subgroup with B symptoms and a mediastinal mass ratio greater than one third the transthoracic diameter. This updated report confirms the efficacy and safety of the MOPP/ABV hybrid program for advanced Hodgkin's disease, which is now being tested in a prospective, randomized, multicenter trial.

AB - Seventy-six patients with previously untreated advanced Hodgkin's disease have been treated with the MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program. Ten patients also received involved field radiation to the mediastinum for residual nodal disease after six cycles of chemotherapy. Of the 74 evaluable patients, 71 (96%) had a complete response. The actuarial relapse-free survival for the complete responders after 62 months off treatment is 90% (median follow-up from treatment completion was 35 months; range, 4 to 62 months). Actuarial overall survival for all 76 patients including all causes of death is 95% (median follow-up time from diagnosis was 43 months; range, 4 to 70 months). Toxicity was modest. Only one death occurred during treatment, and toxicity-related hospitalization was necessary for only 8% of patients. Failure analysis indicates that a disproportionate number of treatment failures occurred in the subgroup with B symptoms and a mediastinal mass ratio greater than one third the transthoracic diameter. This updated report confirms the efficacy and safety of the MOPP/ABV hybrid program for advanced Hodgkin's disease, which is now being tested in a prospective, randomized, multicenter trial.

UR - http://www.scopus.com/inward/record.url?scp=0023324045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023324045&partnerID=8YFLogxK

M3 - Article

C2 - 2438780

AN - SCOPUS:0023324045

VL - 24

SP - 35

EP - 40

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2 SUPPL. 1

ER -